The study found that a specific area of the hair follicle helps start hair growth by reducing the blocking effects on certain cells and controlling growth signals.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
Oral minoxidil and finasteride can lead to quick hair growth, with some users noticing changes in as little as 2-3 weeks, though head hair may take longer. Many prefer oral minoxidil over topical due to convenience, and some also use ketoconazole shampoo and other topical treatments.
A 21-year-old experienced severe hair loss after stress and tried PRP, mesotherapy, and a topical finasteride + minoxidil solution, which was costly and inconvenient. They switched to dutasteride, experienced heavy shedding, and are considering switching to finasteride, with advice to consult a qualified doctor for further guidance.